148 related articles for article (PubMed ID: 30782771)
21. Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study : Palivizumab prophylaxis in children with congenital heart disease.
Ratti C; Greca AD; Bertoncelli D; Rubini M; Tchana B
Ital J Pediatr; 2023 Jan; 49(1):4. PubMed ID: 36631870
[TBL] [Abstract][Full Text] [Related]
22. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia.
Piñeros JG; De la Hoz-Valle J; Galvis C; Celis A; Ovalle O; Sandoval CC; Orrego J; Vides S; Rojas I; Bustamante H; Gallón C; Mesa JA
J Infect Dev Ctries; 2021 Nov; 15(11):1708-1713. PubMed ID: 34898500
[TBL] [Abstract][Full Text] [Related]
24. Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study.
Kamori A; Morooka Y; Yamamura K; Chong PF; Kuga N; Takahata Y; Sagawa K; Furuno K
Medicine (Baltimore); 2021 Nov; 100(47):e27952. PubMed ID: 34964779
[TBL] [Abstract][Full Text] [Related]
25. The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut.
Banerji A; Panzov V; Young M; Lee BE; Mamdani M; Giles BL; Dennis M; Morel J; Bisson D; Paes BA; Hui C; Mahony J
Can Respir J; 2014; 21(3):185-9. PubMed ID: 24367792
[TBL] [Abstract][Full Text] [Related]
26. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
Meissner HC; Long SS;
Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
[TBL] [Abstract][Full Text] [Related]
27. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
[TBL] [Abstract][Full Text] [Related]
28. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
29. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
30. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab.
Kassis C; Champlin RE; Hachem RY; Hosing C; Tarrand JJ; Perego CA; Neumann JL; Raad II; Chemaly RF
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1265-71. PubMed ID: 20304082
[TBL] [Abstract][Full Text] [Related]
31. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants.
Duppenthaler A; Gorgievski-Hrisoho M; Aebi C
Swiss Med Wkly; 2001 Mar; 131(11-12):146-51. PubMed ID: 11416887
[TBL] [Abstract][Full Text] [Related]
32. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
[TBL] [Abstract][Full Text] [Related]
33. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
[TBL] [Abstract][Full Text] [Related]
35. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals.
Murray J; Saxena S; Sharland M
Arch Dis Child; 2014 May; 99(5):469-73. PubMed ID: 24464977
[TBL] [Abstract][Full Text] [Related]
36. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
Groothuis JR; Hoopes JM; Hemming VG
Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
[TBL] [Abstract][Full Text] [Related]
37. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
Feltes TF; Sondheimer HM; Tulloh RM; Harris BS; Jensen KM; Losonsky GA; Griffin MP;
Pediatr Res; 2011 Aug; 70(2):186-91. PubMed ID: 21522037
[TBL] [Abstract][Full Text] [Related]
38. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.
Pediatrics; 1998 Sep; 102(3):531-7. PubMed ID: 9724660
[TBL] [Abstract][Full Text] [Related]
39. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study.
Elhalik M; El-Atawi K; Dash SK; Faquih A; Satyan AD; Gourshettiwar N; Khan A; Varughese S; Ramesh A; Khamis E
Can Respir J; 2019; 2019():2986286. PubMed ID: 31871513
[TBL] [Abstract][Full Text] [Related]
40. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis.
Winterstein AG; Eworuke E; Xu D; Schuler P
Pediatr Pulmonol; 2013 Sep; 48(9):874-84. PubMed ID: 23139089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
